A 48-year-old male with CLL and concomitant AIHA unresponsive to chlorambucil was treated with fludarabine. The remission of CLL and improvement of the AIHA was achieved, but the patient remained steroid dependent. Therefore, high-dose chemotherapy followed by CD34-selected autologous peripheral blood stem cells transplantation was performed and this led to long-term clinical, immunophenotypic and molecular remission with disappearance of AIHA. Twenty-three months later, the CLL recurred with signs of AIHA. In this patient with AIHA, HDC and selected CD34 ؉ cells completely, though temporarily, controlled both CLL and associated immune complications. This case illustrates the potential application of this approach in the management of CLL patients with immune complications.
Chronic lymphocytic leukemia (CLL) is an indolent disease historically considered to be incurable. It is often associated with autoimmune complications, especially autoimmune hemolytic anemia (AIHA), occurring in approximately 10 to 20% of cases. 1 Recent developments, including establishment of purine analogs such as fludarabin monophosphate (FAMP) as an effective agent with a high remission rate 2 and the possibility of purging grafts of tumour cells (eg by CD34 ϩ selection) also allow depletion of cells possibly involved in concomitant immune complications (ie T cells). 3, 4 This raised new perspectives in the treatment of CLL. The possibly curative potential of the above approaches suggests incorporation of these strategies, ie the use of purine analogs followed by high-dose chemotherapy (HDC) and autografting (with or without purging), in the treatment of CLL, particularly for younger patients with immune complications. We report here a CLL patient with AIHA persisting after FAMP treatment (although nodular PR in BM was achieved) who responded to subsequent HDC with CD34 ϩ selected autologous blood stem cells which resulted in nearly 2 years of clinical, immunophenotypic and molecular CR with disappearance of AIHA.
Case report
A 48-year-old male was diagnosed as having CLL stage III RAI in March 1996. He presented with clinical signs of hemolysis and, according to strong DAT and IAT positivity, associated AIHA was diagnosed. He received two courses of chlorambucil and prednisone but without any effect on lymphocytosis and hemolysis, so the therapy was switched to purine analogues. Six cycles of therapy with FAMP (5 day course with 25 mg/m 2 /day) along with continuous prednisone (20-30 mg daily) resulted in nodular partial remission in the bone marrow and gradual diminution of clinical signs of hemolysis with achievement of negativity of both Coomb's tests. However, attempts to reduce corticosteroids led again to both DAT and IAT positivity. It was then elected to proceed to high-dose chemotherapy with autologous CD34 ϩ selected peripheral blood stem cell (PBSC) transplantation. PBSCs were mobilized in October 1996 using cyclophosphamide 3 g/m 2 and G-CSF (filgrastim) 10 g/kg/day. Leukaphereses were performed on a continuous cell separator (Cobe Spectra, Lakewood, CO, USA). The first unmanipulated product served as a back-up and the second and third apheresis products were subject to CD34 ϩ selection using a CEPRATE SC immunoaffinity column (CellPro, Bothell, WA, USA), according to the manufacturer's manual. FACS analysis was done on a Coulter Epics XL (Coulter Corporation, Hialeah, FL, USA) with CD45, CD19, CD5 and CD3 monoclonal antibodies (all from Coulter-Immunotech, Marseille, France). Graft characteristics before and after the procedure are shown in Table 1 . The purified fraction contained 2.35 ϫ 10 6 CD34 ϩ cells/kg (recovery 43.6%) with purity of 71.6%. The total CD3 ϩ and CD5 ϩ CD19 ϩ cell doses before selection were 4.40 ϫ 10 9 and 2.51 ϫ 10 9 , respectively, and after selection 2.56 ϫ 10 6 and 2.33 ϫ 10
6
, respectively. The procedure therefore gave purging efficacy of about 3-logs. Molecular analyses of the graft pre-and post-selection were not done. HDC was given immediately using BEAM (BCNU 300 mg/m 2 day Ϫ6, etoposide 200 mg/m 2 and araAutologous CD34 ؉ cell transplantation after FAMP for CLL P Jindra et al 216 C 400 mg/m 2 day Ϫ5 to Ϫ2, melphalan 140 mg/m 2 day Ϫ1) followed by infusion (day 0) of immunoselected PBSC in November 1996. Uncomplicated engraftment occurred with neutrophil recovery to 0.5 ϫ 10 9 /l on day ϩ17 and platelet recovery to 20 ϫ 10 9 on day ϩ19 post-transplant, respectively and he was discharged home on day ϩ21. During this early post-transplant period, both Coomb's tests became negative and thus corticoids could be stopped. Peripheral blood and trephine biopsy 1 month after transplantation showed no evidence of CLL and achievement of CR was confirmed by immunophenotypic and molecular assays, ie PCR for IgH rearrangement.
5 Regular re-examinations of disease status during follow-up by clinical, morphological, immunophenotypic and molecular methods failed to demonstrate any evidence of residual CLL together with no evidence of AIHA as documented by persistent Coomb's test negativity. However, 23 months after transplantation, the patient became positive by PCR and FACS and over the next month both Coomb's tests were positive. Recurrence of CLL was subsequently confirmed by clinical and morphological assessment. To date the patient is alive with CLL corresponding to stage 0 according to Rai, with laboratory signs of clinically compensated AIHA not requiring any therapy. Allogeneic BMT from his siblings is considered.
Discussion
A number of developments in the 1990s have allowed consideration of BMT in CLL patients. Purine analogs, such as fludarabin monophosphate (FAMP), have been shown to induce high remission rates reaching 80% with a CR rate of up to 60% in previously untreated patients. 6 Techniques for depletion of leukemia cells present in the graft became widely available. Some of them (such as CD34 ϩ cell selection) suggest possible effects on autoimmune complications. 4 Finally, improved supportive care has allowed more extensive use of dose intensive therapies in older patients. Due to this, there is an increasing number of reports on autotransplants in CLL patients, 7-9 mostly concerning patients with advanced or refractory disease. This is not the case here because our patient had reached nodular PR after FAMP treatment and the decision to proceed to high-dose therapy was made on the basis of a persisting autoimmune complication. A CD34 ϩ selected graft was chosen in the hope of reducing not only graft-contaminating lymphoma cells, but also cells participating in the autoimmune process. To our knowledge this is the first published case in which the main indication for the described strategy was not only the refractoriness of primary disease (ie CLL) or consolidation of achieved remission but the attempt to control persisting autoimmune complication and to avoid long-term corticoids with all its inevitable sideeffects.
In spite of the persistent presence of CLL cells in graft after CD34
ϩ selection (Table 1) , this incomplete tumor eradication from the graft did not compromise the achievement of molecular remission in our case, in agreement with the experience of others. 10, 11 Although a clear-cut benefit of purging has not been shown for any disease to date, there is some evidence that relapse after autologous stem cell transplantation may arise from cells reinfused with the graft 12 and thus it is still believed that purging of the graft by any means could be advantageous. The minimisation of graft lymphoma contamination might be helpful in achieving complete remission at the molecular level after transplant which seems to correlate with a lower rate of disease recurrence as shown by some. 9, 12 Indeed, the relatively long-lasting (if considering the nature of CLL) disease-free interval seen in our patient seems to relate to PCR negativity achieved early after transplantation and thus corroborates this assumption. However, interpretation of the above should be cautious, because the technique used for molecular monitoring in this case (ie PCR of IgH region with agarose gel separation of products) 5 has a relatively low sensitivity allowing the detection of only approximately one tumor cell in 10 2 -10 3 normal cells (as determined by dilution experiments, data not shown) and this does not exceed significantly the sensitivity of immunophenotyping by FACS. So our case neither confirms nor refutes the premise that PCR negativity is equivalent to chance for a definitive cure in lymphoma patients.
Rather more controversial remains the real contribution of CD34 ϩ cell selection in managing the immune complications after HDC. The mechanism behind hemolysis in CLL is unclear but it is generally accepted that autoimmune phenomenon is due to polyclonal autoantibodies restricted to blood cell self-antigens and that T cells are actively involved in this process. 13 This may point to a possible role for T cell depletion of the graft in suppression of the concomitant autoimmune process and animal studies, as well as a consensus report from EULAR and EBMT on the use of stem cell transplants in autoimmune diseases, are in favor of such a procedure. 14, 15 Whether this is relevant also in CLL remains questionable because its autoimmune complication is tightly linked to, or more exactly directly caused by underlying malignant disease. This gives rise to the assumption that the tumor-ablative effect of HDC rather than the CD34 ϩ cell selection may be responsible for the control of the AIHA. In other words, the immune cell depletion of the graft was of no, or at best of little significance in this setting. The fact that the signs of AIHA persisted in accordance with nodular residual disease in bone marrow before HDC, and again emerged just after relapse of CLL 12 months after immune reconstitution (data not shown), support this. However, conclusive data on this issue are still lacking and whether or not there will be any role for graft engineering in the treatment of CLL with concomitant autoimmune complications needs further study.
FAMP treatment alone may induce severe autoimmune hemolysis 16 and this associated complication was also of concern in our patient. Fortunately this was not the case, because the initiation of FAMP led to improvement of AIHA (yet requiring corticoids) as mentioned above. This was probably related to CLL treatment response and this observation is in agreement with DiRaimondo et al. 17 In addition, this again underlines the key importance of CLLdirected therapy (ie disease eradication) on the management of AIHA rather than of immune cell engineering.
In conclusion, CD34-purified PBSC transplantation in a CLL patient in good clinical remission but with persisting AIHA led to long-lasting molecular remission of lymphoma and control of the AIHA. Although the response was not definitive and both CLL and later AIHA eventually recurred, this approach appears interesting and should be considered in this subset of CLL patients. However the role of the manipulation of immune cells in the autograft in improving the response of autoimmune disease remains open and needs additional data.
